10:26 EST Pactiv Evergreen (PTVE) draws interest from Apollo’s Novolex, Bloomberg reports
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTVE:
- Pactiv Evergreen’s Q3 2024 Financial Performance and Outlook
- Pactiv Evergreen Faces Revenue Decline Amid Strategic Shifts
- Pactiv Evergreen narrows FY24 adjusted EBITDA view to $800M-$820M
- Pactiv Evergreen reports Q3 adjusted EPS 36c, consensus 36c
- PTVE Earnings Report this Week: Is It a Buy, Ahead of Earnings?